On the contrary, about one-half of ESRD patients who were administered with other antidiabetic drugs suffered from PD catheter failure at the end of study, implying DPP4 inhibitor offered a better protective effect against peritoneal sclerosis or fibrosis compared to other non-DPP4 inhibitors antidiabetic drugs (Tables 2 and 3). This evidence concerns the gene DPP4 and fibrosis.